BioCentury | May 4, 2015
Company News

Resverlogix, Shenzhen Hepalink Pharmaceutical deal

...responsible for development costs in the regions. Subject to the completion of the transaction, shareholder Eastern Capital Ltd....
BioCentury | Apr 28, 2015
Company News

Hepalink gains rights to Resverlogix's RVX-208 in China

...warrants at C$2.67. Hepalink is entitled to nominate one member for Resverlogix's board. Existing shareholder Eastern Capital Ltd....
BioCentury | Nov 24, 2011
Financial News

Resverlogix planning private placement

...through the sale of up to 14.8 million shares at C$1.18 in a private placement. Eastern Capital Ltd....
Items per page:
1 - 3 of 3
BioCentury | May 4, 2015
Company News

Resverlogix, Shenzhen Hepalink Pharmaceutical deal

...responsible for development costs in the regions. Subject to the completion of the transaction, shareholder Eastern Capital Ltd....
BioCentury | Apr 28, 2015
Company News

Hepalink gains rights to Resverlogix's RVX-208 in China

...warrants at C$2.67. Hepalink is entitled to nominate one member for Resverlogix's board. Existing shareholder Eastern Capital Ltd....
BioCentury | Nov 24, 2011
Financial News

Resverlogix planning private placement

...through the sale of up to 14.8 million shares at C$1.18 in a private placement. Eastern Capital Ltd....
Items per page:
1 - 3 of 3